
    
      Participants eligible to enroll into this rollover protocol will begin study treatment within
      2-5 days of their Day 28 study termination visit in Protocol 501-CL-003 (NCT00441090).
      Participants who met the primary efficacy response criterion in Protocol 501-CL-003 will
      continue receiving the same study treatment to which they were assigned in the previous
      protocol in a double-blinded manner, these being one of the following 5 treatments:

        -  avatrombopag 2.5 mg daily

        -  avatrombopag 5 mg daily

        -  avatrombopag 10 mg daily

        -  avatrombopag 20 mg daily

        -  placebo

      Participants who did not meet the primary efficacy response criterion in Protocol 501-CL-003
      who otherwise meet the eligibility criteria for this rollover protocol will be offered open
      label avatrombopag 10 mg daily.

      This is a parallel group, rollover study.
    
  